IL-2 CAR T cells were robust in killing tumor cells both in vitro and in vivo, but overtime CAR T cells expanded in IL-7/15 outperformed IL-2 CAR T cells with increased expansion and improved persistence. Here, IL7 is linked to neoplasm.